FDA’s Zohydro ER Headache Worsening: States, DOJ Question Approval
Executive Summary
Massachusetts’ ban on the single-entity hydrocodone signals a new kind of activism by states, and there even appears to be disunity within the Obama administration about the value of the long-acting opioid as Attorney General Holder tells Congress he is “a little baffled” by FDA’s approval and will be evaluating the basis for the decision.
You may also be interested in...
What Might FDA Do Post Roe? Eliminate Mifepristone REMS
Attorneys say the biggest step FDA could take to expand access to medication abortion would be to eliminate REMS requirement for mifepristone. Timeline notes steps Biden administration and Congress have taken since the Supreme Court’s ruling overturning the right to an abortion.
Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights
Clinicians in states that ban abortion could face criminal prosecution for providing mifepristone. Access to medical abortion ‘is not a panacea’ if the court overrules Roe v. Wade as people using the drug face risks from aggressive prosecutors, ACLU attorney says.
The Short And Controversial Life Of Zohydro Comes To An End
US FDA’s approval of the opioid over resounding opposition of an advisory committee has haunted the agency, and it has imperiled both of Robert Califf’s nominations to be commissioner. The latest company to own Zohydro stopped selling it and FDA withdrew approval of its NDA.